WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005063289) CD40 ANTIBODY FORMULATION AND METHODS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/063289    International Application No.:    PCT/IB2004/004103
Publication Date: 14.07.2005 International Filing Date: 09.12.2004
Chapter 2 Demand Filed:    17.12.2004    
IPC:
A61K 39/395 (2006.01), C07K 16/28 (2006.01)
Applicants: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US) (For All Designated States Except US).
BEDIAN, Vahe [US/US]; (US) (For US Only).
CUSMANO, John, Daniel [US/US]; (US) (For US Only).
GLADUE, Ronald, Paul [US/US]; (US) (For US Only)
Inventors: BEDIAN, Vahe; (US).
CUSMANO, John, Daniel; (US).
GLADUE, Ronald, Paul; (US)
Agent: FULLER, Grover, F., Jr.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US)
Priority Data:
60/531,639 22.12.2003 US
Title (EN) CD40 ANTIBODY FORMULATION AND METHODS
(FR) FORMULATION D'ANTICORPS CD40 ET MÉTHODES
Abstract: front page image
(EN)The present invention provides a method of treating tumor in a patient comprising administering to said patient a CD40 agonist antibody according to an intermittent dosing schedule. The present invention also provides a method of treating tumor in a patient comprising administering a combination of a CD40 agonist antibody and a DNA replication inhibitor. Also provided is a formulation for use in the treatment.
(FR)Selon cette méthode de traitement de tumeurs chez un patient, on administre au patient un anticorps agoniste de CD40 selon un plan d'administration intermittente. L'invention concerne également une méthode de traitement de tumeurs chez un patient qui comprend l'administration d'une combinaison d'un anticorps agoniste de CD40 et d'un inhibiteur de la réplication de l'ADN, ainsi qu'une formulation utilisée dans le traitement.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)